Merck and Endocyte announce withdrawal of conditional marketing authorization applications for Vintafolide and companion imaging components, Etarfolat

20-05-2014 Business Wire HealthComments (0)

AlcoholsBusiness FinanceEndocyteetarfolatideFolic acidHealth Medical PharmaMarketing authorizationMerck KGaAPharmaceuticalUSAvintafolide

Merck and Endocyte announce withdrawal of conditional marketing authorization applications for Vintafolide and companion imaging components, Etarfolatide and Intravenous (IV) folic acid in Europe

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top